Published in Proc Natl Acad Sci U S A on March 01, 2017
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res (2008) 54.83
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Cancer genome landscapes. Science (2013) 25.33
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (1994) 8.73
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Cells of origin in cancer. Nature (2011) 6.85
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Breast cancer statistics, 2011. CA Cancer J Clin (2011) 6.12
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
PANTHER version 10: expanded protein families and functions, and analysis tools. Nucleic Acids Res (2015) 3.35
The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (2006) 3.17
An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet (2011) 2.99
Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis (2004) 2.40
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol (2009) 2.32
ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression. Nature (2014) 2.24
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet (2004) 2.10
A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat (2010) 2.03
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist (2011) 2.02
A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc (2009) 1.95
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat (2006) 1.92
Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol (2006) 1.92
A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res (2009) 1.86
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer (2007) 1.75
SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One (2013) 1.74
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2005) 1.73
Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res (2008) 1.72
Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell (2012) 1.65
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
The CHEK2 gene and inherited breast cancer susceptibility. Oncogene (2006) 1.62
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60
Oncogenic transformation and experimental models of human cancer. Front Biosci (2008) 1.59
Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development (2004) 1.58
Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol (2012) 1.53
On the nature of susceptibility to cancer. The presidential address. Cancer (1980) 1.49
Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol (2011) 1.29
Tumor type-dependent function of the par3 polarity protein in skin tumorigenesis. Cancer Cell (2012) 1.28
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet (2015) 1.23
Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics (2011) 1.19
Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol (2010) 1.17
Mutations in the p53 gene in primary human breast cancers. Cancer Res (1991) 1.15
Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun (2013) 1.12
A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. Proc Natl Acad Sci U S A (2011) 1.09
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat (2010) 1.08
Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis. Cell Growth Differ (2001) 1.08
Data-driven approach to predict survival of cancer patients: estimation of microarray genes' prediction significance by Cox proportional hazard regression model. IEEE Eng Med Biol Mag (2009) 1.08
Increased risk of breast cancer in women with NF1. Am J Med Genet A (2012) 1.07
Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics (2005) 1.07
Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene (2009) 1.07
The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat (2007) 1.06
Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet (2013) 1.04
Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics (2012) 1.04
Discovery of the BMPR1A promoter and germline mutations that cause juvenile polyposis. Hum Mol Genet (2010) 1.00
Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer (2013) 0.98
PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res (2001) 0.94
Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci (2008) 0.90
EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. Mol Carcinog (2009) 0.89
A complex containing LPP and α-actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells. J Cell Sci (2013) 0.89
Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget (2015) 0.89
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. BMC Cancer (2014) 0.85
Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B. Int J Oncol (2008) 0.85
Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Oncogene (2015) 0.82
Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A. Oncogenesis (2014) 0.79
Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development. Oncotarget (2015) 0.77